1 January 2020 in International Journal of Medical Sciences
Artificial intelligence (AI), as an advanced science technology, has been widely used in medical fields to promote medical development, mainly applied to early detections, disease diagnoses, and management. Owing to the huge number of patients, kidney disease remains a global health problem. Challenges remain in its diagnosis and treatment. AI could take individual conditions into account, produce suitable decisions and promise to make great strides in kidney disease management. Here, we review the current studies of AI applications in kidney disease in alerting systems, diagnostic assistance, guiding treatment and evaluating prognosis. Although the number of studies related to AI applications in kidney disease is small, the potential of AI in the management of kidney disease is well recognized by clinicians; AI will greatly enhance clinicians' capacity in their clinical practice in the future.
25 November 2019 in International Urology and Nephrology
10 August 2020 in Scientific Reports
The pathogenesis of diabetic nephropathy is not completely understood, and the effects of existing treatments are not satisfactory. Various public platforms already contain extensive data for deeper bioinformatics analysis. From the GSE30529 dataset based on diabetic nephropathy tubular samples, we identified 345 genes through differential expression analysis and weighted gene coexpression correlation network analysis. GO annotations mainly included neutrophil activation, regulation of immune effector process, positive regulation of cytokine production and neutrophil-mediated immunity. KEGG pathways mostly included phagosome, complement and coagulation cascades, cell adhesion molecules and the AGE-RAGE signalling pathway in diabetic complications. Additional datasets were analysed to understand the mechanisms of differential gene expression from an epigenetic perspective. Differentially expressed miRNAs were obtained to construct a miRNA-mRNA network from the miRNA profiles in the GSE57674 dataset. The miR-1237-3p/SH2B3, miR-1238-5p/ZNF652 and miR-766-3p/TGFBI axes may be involved in diabetic nephropathy. The methylation levels of the 345 genes were also tested based on the gene methylation profiles of the GSE121820 dataset. The top 20 hub genes in the PPI network were discerned using the CytoHubba tool. Correlation analysis with GFR showed that SYK, CXCL1, LYN, VWF, ANXA1, C3, HLA-E, RHOA, SERPING1, EGF and KNG1 may be involved in diabetic nephropathy. Eight small molecule compounds were identified as potential therapeutic drugs using Connectivity Map.
29 February 2020 in Research Square
Background: Various public platforms have contained extensive data for deeper bioinformatics analysis. The pathogenesis of diabetic nephropathy is always a hot topic and the underlying molecular events are not completely clear. Methods: Differential expression analysis and weighted correlation network analysis (WGCNA) were applied to screen meaningful gene in GSE30529. The combined result was used for gene ontology (GO) annotation and KEGG pathway enrichment analysis. STRING was used for protein-protein interaction (PPI) network construction and Cytoscape software was used for hub gene identification. Gene methylation profile GSE121820 and miRNA profile GSE51674 were also acquired to perform multi-omics analysis. Clinical features were obtained form Nephroseq and potential drugs were identified by CMap. Results: 345 genes were obtained form GSE30529 after differential expression analysis and WGCNA. GO analysis mainly included neutrophil activation, regulation of immune effector process, positive regulation of cytokine production and neutrophil mediated immunity. KEGG pathway analysis mostly included phagosome, complement and coagulation cascades, cell adhesion molecules and AGE-RAGE signaling pathway in diabetic complications. 16 down regulated miRNAs were obtained from GSE57674 to construct miRNA-mRNA network. Top 20 genes were discerned from PPI network and there were DNA methylation differences in 15 genes among them. Correlation analysis showed SYK, CXCL1, LYN, VWF, ANXA1, C3, HLA-E, RHOA, SERPING1, EGF and KNG1 may involved in DN. 10 small molecule compounds have been identified as potential therapeutic drugs. Conclusion: We screened 11 target genes and suggested C3 may serve as a therapeutic target in diabetic nephropathy.